Brendan Frett

List of Publications by Year
in descending order

46	989	393982	454577
papers	citations	19 h-index	30 g-index

57	57	57	1561
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators. Journal of Medicinal Chemistry, 2013, 56, 5219-5230.	2.9	104
2	Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. Journal of Clinical Investigation, 2017, 127, 3075-3089.	3.9	86
3	Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. Journal of Medicinal Chemistry, 2019, 62, 1731-1760.	2.9	58
4	Selective Reduction of Halogenated Nitroarenes with Hydrazine Hydrate in the Presence of Pd/C. Synlett, 2014, 25, 1403-1408.	1.0	55
5	Efficient Access to 2,3-Diarylimidazo[1,2-a]pyridines via a One-Pot, Ligand-Free, Palladium-Catalyzed Three-Component Reaction under Microwave Irradiation. Organic Letters, 2014, 16, 3016-3019.	2.4	51
6	Synthesis of tetrazolo-fused benzodiazepines and benzodiazepinones by a two-step protocol using an Ugi-azide reaction for initial diversity generation. Tetrahedron, 2012, 68, 5606-5611.	1.0	41
7	Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with inÂvitro and inÂvivo antitumor activities. European Journal of Medicinal Chemistry, 2017, 126, 1083-1106.	2.6	41
8	Metal-free, efficient hydrazination of imidazo[1,2-a]pyridine with diethyl azodicarboxylate in neutral media. Organic and Biomolecular Chemistry, 2015, 13, 2958-2964.	1.5	36
9	Fragmentâ€Based Discovery of a Dual panâ€RET/VEGFR2 Kinase Inhibitor Optimized for Singleâ€Agent Polypharmacology. Angewandte Chemie - International Edition, 2015, 54, 8717-8721.	7.2	33
10	Catalyst free, C-3 functionalization of imidazo[1,2-a]pyridines to rapidly access new chemical space for drug discovery efforts. Chemical Communications, 2018, 54, 12954-12957.	2.2	31
11	A p-toluenesulfinic acid-catalyzed three-component Ugi-type reaction and its application for the synthesis of Î±-amino amides and amidines. Tetrahedron Letters, 2013, 54, 2340-2343.	0.7	30
12	Recent advances in the development of polycyclic skeletons via Ugi reaction cascades. Molecular Diversity, 2018, 22, 503-516.	2.1	28
13	The Exploration of Chirality for Improved Druggability within the Human Kinome. Journal of Medicinal Chemistry, 2020, 63, 441-469.	2.9	27
14	Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells. Bioorganic and Medicinal Chemistry, 2018, 26, 3899-3908.	1.4	24
15	Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. European Journal of Medicinal Chemistry, 2015, 94, 123-131.	2.6	22
16	Therapeutic Melting Pot of Never in Mitosis Gene A Related Kinase 2 (Nek2): A Perspective on Nek2 as an Oncology Target and Recent Advancements in Nek2 Small Molecule Inhibition. Journal of Medicinal Chemistry, 2014, 57, 5835-5844.	2.9	21
17	Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression. European Journal of Medicinal Chemistry, 2020, 203, 112589.	2.6	21
18	Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry, 2021, 216, 113265.	2.6	21

#	Article	IF	Citations
19	Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation. European Journal of Medicinal Chemistry, 2014, 86, 714-723.	2.6	20
20	Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology. Journal of Medicinal Chemistry, 2020, 63, 4506-4516.	2.9	20
21	ProteoViz: a tool for the analysis and interactive visualization of phosphoproteomics data. Molecular Omics, 2020, 16, 316-326.	1.4	19
22	An expeditious approach to access 2-arylimidazo[1,2-a]pyridin-3-ol from 2-amino pyridine through a novel Petasis based cascade reaction. Tetrahedron Letters, 2014, 55, 1281-1284.	0.7	18
23	Use of Imidazo[1,2â€a]pyridine as a Carbonyl Surrogate in a Mannichâ€Like, Catalyst Free, Oneâ€Pot Reaction. European Journal of Organic Chemistry, 2019, 2019, 770-777.	1.2	17
24	Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2020, 206, 112691.	2.6	16
25	Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT. Scientific Reports, 2018, 8, 3722.	1.6	13
26	Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-a]pyridine derivatives. Tetrahedron, 2018, 74, 4592-4600.	1.0	13
27	Structural Characterization of the Aurora Kinase B â€œDFG-flipâ€•Using Metadynamics. AAPS Journal, 2020, 22, 14.	2.2	13
28	Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. Journal of Medicinal Chemistry, 2021, 64, 11747-11773.	2.9	13
29	Intramolecular cyclization of imidazo[1,2-a]pyridines via a silver mediated/palladium catalyzed Câ€“H activation strategy. Organic Chemistry Frontiers, 2019, 6, 2234-2239.	2.3	12
30	Preclinical activity of MBM-5 in gastrointestinal cancer by inhibiting NEK2 kinase activity. Oncotarget, 2016, 7, 79327-79341.	0.8	11
31	Diversityâ€Oriented Synthesis of Functionalized Imidazopyridine Analogues with Antiâ€Cancer Activity through a Transitionâ€Metal Free, Oneâ€pot Cascade Reaction. Advanced Synthesis and Catalysis, 2018, 360, 3655-3661.	2.1	10
32	Identification of pyrazine-based TrkA inhibitors: design, synthesis, evaluation, and computational modeling studies. MedChemComm, 2014, 5, 1507-1514.	3.5	9
33	One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction. Chemical Communications, 2020, 56, 2194-2197.	2.2	8
34	Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor. European Journal of Medicinal Chemistry, 2021, 225, 113776.	2.6	8
35	Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. Journal of Clinical Investigation, 2020, 130, 6187-6187.	3.9	7
36	FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms. RSC Medicinal Chemistry, 2022, 13, 798-816.	1.7	7

#	Article	IF	Citations
37	Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases. Scientific Reports, 2021, 11, 16103.	1.6	5
38	Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose. Journal of Medicinal Chemistry, 2022, 65, 1536-1551.	2.9	4
39	Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach. ChemMedChem, 2021, 16, 1605-1608.	1.6	3
40	Targeting the Kâ€Ras/PDEÎ´ Proteinâ€“Protein Interaction: The Solution for Rasâ€Ðriven Cancers or Just Another Therapeutic Mirage?. ChemMedChem, 2013, 8, 1620-1622.	1.6	2
41	Discovery and biological evaluation of phthalazines as novel non-kinase TGFÎ² pathway inhibitors. European Journal of Medicinal Chemistry, 2021, 223, 113660.	2.6	2
42	Synthesis of Constrained Heterocycles Employing Two Postâ€Ugi Cyclization Methods for Rapid Library Generation with In Cellulo Activity. ChemistrySelect, 2017, 2, 11821-11825.	0.7	1
43	Discovery of 4-aminoquinolines as highly selective TGFÎ²R1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology. European Journal of Medicinal Chemistry, 2021, 225, 113763.	2.6	1
44	Targeting TGF-Î²: triumphs and challenges. Future Medicinal Chemistry, 2022, , .	1.1	1
45	(Z)-N-tert-Butyl-2-(4-methoxyanilino)-Nâ€²-(4-methoxyphenyl)-2-phenylacetimidamide. Acta Crystallographica Section E: Structure Reports Online, 2013, 69, o902-o902.	0.2	0
46	Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. Journal of Clinical Investigation, 2020, 130, 5027-5027.	3.9	0